Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Axial Spondyloarthritis (axSpA) Market Growth Evolved From 2024 To 2025, And What’s Ahead?

There has been significant growth in the axial spondyloarthritis (axspa) market size over the past few years. The market value is projected to rise from $6.08 billion in 2024 to $6.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.0%. This expansion during the historical period is credited to enhanced diagnostic tools, advancement in biological therapies, increased awareness of the disease, progress in genetic research, and evolution in clinical trials.

The market size of axial spondyloarthritis (axspa) is predicted to experience a substantial increase in the upcoming years, expanding to$9.03 billion in 2029 with a compound annual growth rate (CAGR) of 8.3%. This rise during the forecast period can be associated with improvements in biomarker detection, customized treatments, the incorporation of digital health, extensive therapy choices, and support from healthcare policies. Key trends in the forecast timeframe encompass strategies for early intervention, patient-focused treatment, the usage of telemedicine and remote consultations, research into disease mechanisms, and collective decision-making.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Axial Spondyloarthritis (axSpA) Market?

The projected growth of the axial spondyloarthritis (axSpa) market is primarily driven by the escalating incidences of spondyloarthritis, a chronic ailment affecting the axial skeleton, including the spine and sacroiliac joints. The surging cases, attributable to an aging population and spinal injuries from minor accidents or falls, are met with numerous treatments that aid pain management, reduce inflammation, and improve quality of life for axSpA patients. For instance, according to the Musculoskeletal Health Report 2023 by Versus Arthritis, a UK-based arthritis support charity, an estimated 60,000 individuals suffered from axial spondyloarthritis as of 2022, with about 2,200 adults receiving a new diagnosis annually. Hence, the upswing in the prevalence of axial spondyloarthritis is steering the growth of the axial spondyloarthritis market.

Which Key Market Segments Comprise the Axial Spondyloarthritis (axSpA) Market and Drive Its Revenue Growth?

The axial spondyloarthritis (axspa)market covered in this report is segmented –

1) By Types: Ankylosing Spondylitis (AS); Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF); Anti-Interleukin Therapy (IL); Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets; Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors; Non-Steroidal Anti-Inflammatory Drugs (NSAID); Conventional Disease Modifying Anti-Rheumatic Drugs; Glucocorticoids; Interleukin Blockers

5) By End-Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS; Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA; Asymptomatic nr-axSpA

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Which Areas Are Leading Regions in the Axial Spondyloarthritis (axSpA) Market Expansion Across the Globe?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theAxial Spondyloarthritis (axSpA) Market Direction?

The key trend that’s gaining traction in the axial spondyloarthritis (axSpA) market is innovation in product development. In order to maintain their market position, leading firms in the axial spondyloarthritis (axSpA) landscape are investing in the development of new medications. For example, in June 2023, Belgium-based pharmaceutical company UCB SA attained New European Commission approval to market BIMZELX (bimekizumab), a drug formulated to treat adults diagnosed with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS), who display signs of inflammation demonstrated by raised C-reactive protein levels. The authorizations from the European Union (EU) constitute the medication’s inaugural worldwide marketing licenses for axial spondyloarthritis.

View the full report here:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

How Is the Axial Spondyloarthritis (axSpA) Market Conceptually Defined?

Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly impacts the axial skeleton, encompassing the spine and sacroiliac joints. It is characterized by inflammation in the sacroiliac joints, resulting in persistent back pain and stiffness.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12590

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model